

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY COSTA RICA	2. DATE OF BIRTH			2a. AGE 45 Years	3. SEX Female	3a. WEIGHT 120.00 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input checked="" type="checkbox"/> OTHER
		Day	Month	Year				Day	Month	Year	
			PRIVACY						JUN	2025	

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
 Other Serious Criteria: Medically Significant
 Hypothyroidism [Hypothyroidism]
 Iron taste [Dysgeusia]
 nausea [Nausea]
 vomiting [Vomiting]
 Stomach Pain [Abdominal pain upper]
 Stomach discomfort [Abdominal discomfort]
 Headache [Headache]
 couldn't sleep [Insomnia]
 Saxenda was not prescribed by a physician [Prescription drug used with (Continued on Additional Information Page)]

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL (Continued on Additional Information Page)		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1) 1.8 mg, qd	16. ROUTE(S) OF ADMINISTRATION #1) Subcutaneous	
17. INDICATION(S) FOR USE #1) overweight (Overweight)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) JUN-2025 / Unknown	19. THERAPY DURATION #1) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description 2021 to Ongoing Current Condition Overweight (Overweight) Unknown to Ongoing Current Condition Migraine (Migraine) since more than 20 years ago		

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888		26. REMARKS Medically Confirmed: No World Wide #: CR-NOVOPROD-1472780
	24b. MFR CONTROL NO. 1472780	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 02-SEP-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 09-SEP-2025	25a. REPORT TYPE <input type="checkbox"/> INITIAL <input checked="" type="checkbox"/> FOLLOWUP: 2	

09-Sep-2025 14:01

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

a prescription]

Case Description: Study ID: 828652-My Healthy Journey

Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).

Patient's height: 160 cm.

Patient's weight: 120 kg.

Patient's BMI: 46.8750.

This serious Solicited Report from COSTA RICA was reported by a Consumer as "Hypothyroidism(Hypothyroidism)" beginning on JUN-2025 , "Iron taste(Taste metallic)" beginning on 15-JUL-2025 , "nausea(Nausea)" beginning on 15-JUL-2025 , "vomiting(Vomiting)" beginning on 15-JUL-2025 , "Stomach Pain(Stomach Pain)" beginning on 15-JUL-2025 , "Stomach discomfort(Stomach discomfort)" beginning on 15-JUL-2025 , "Headache(Headache)" beginning on JUN-2025 , "couldn't sleep(Sleep difficult)" beginning on 15-JUL-2025 , "Saxenda was not prescribed by a physician(Prescription drug used without a prescription)" beginning on JUN-2025 and concerned a 45 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from JUN-2025 to AUG-2025 for "overweight".

Dosage Regimens:

Saxenda: ??-JUN-2025 to Not Reported, Not Reported to ??-AUG-2025;

Current Condition: Overweight, Migraine

Historical Condition: obesity.

Treatment medications included - GRAVOL(DIMENHYDRINATE).

On an unknown date in JUN-2025, patient started using Saxenda (not prescribed by physician), experienced hypothyroidism and headache, patient reported that symptom has decreased. Frequency of headache was every day, and it lasted all day, on both sides of the head.

Patient did not have any family history of headache. Headache has not been triggered by specific factors like light, noise, food, etc.

On 15-JUL-2025, patient experienced nausea, iron taste, could not sleep and eat due to nausea, stomach discomfort and experienced intense stomach pain, one occasion when it caused vomiting in the early morning. Patient refers that this occurred when started with the 3.0 mg dose. Patient reported that on that night, couldn't sleep due to significant Stomach discomfort, and in the morning, vomited. That day, Patient couldn't eat anything at all because the nausea and stomach pain were significant.

Patient also mentioned that no matter how much brushes the teeth, the iron taste doesn't disappear. Patient reported the use of GRAVOL (Dimenhydrinate) for treating the adverse events.

The patient had not recently switched from another product (within the last 3 months). This was the first time, patient was using Saxenda. Product was received in the original packaging.

Batch Number for Saxenda was requested.

Action taken to Saxenda was reported as Product discontinued due to AE.

The outcome for the event "Hypothyroidism(Hypothyroidism)" was Not recovered.

The outcome for the event "Iron taste(Taste metallic)" was Not yet recovered.

On AUG-2025 the outcome for the event "nausea(Nausea)" was Recovered.

On 12-AUG-2025 the outcome for the event "vomiting(Vomiting)" was Recovered.

On 12-AUG-2025 the outcome for the event "Stomach Pain(Stomach Pain)" was Recovered.

On 12-AUG-2025 the outcome for the event "Stomach discomfort(Stomach discomfort)" was Recovered.

The outcome for the event "Headache(Headache)" was Not yet recovered.

The outcome for the event "couldn't sleep(Sleep difficult)" was Not yet recovered.

On AUG-2025 the outcome for the event "Saxenda was not prescribed by a physician(Prescription drug used without a prescription)" was Recovered.

Reporter's causality (Saxenda) -

Hypothyroidism(Hypothyroidism) : Unknown

Iron taste(Taste metallic) : Possible

09-Sep-2025 14:01

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

nausea(Nausea) : Possible
vomiting(Vomiting) : Possible
Stomach Pain(Stomach Pain) : Possible
Stomach discomfort(Stomach discomfort) : Possible
Headache(Headache) : Unknown
couldn't sleep(Sleep difficult) : Possible
Saxenda was not prescribed by a physician(Prescription drug used without a prescription) : Unknown

Company's causality (Saxenda) -

Hypothyroidism(Hypothyroidism) : Unlikely
Iron taste(Taste metallic) : Possible
nausea(Nausea) : Possible
vomiting(Vomiting) : Possible
Stomach Pain(Stomach Pain) : Possible
Stomach discomfort(Stomach discomfort) : Possible
Headache(Headache) : Possible
couldn't sleep(Sleep difficult) : Possible
Saxenda was not prescribed by a physician(Prescription drug used without a prescription) : Possible

Since last submission the case has been updated with the following:

Product stop date added, action taken updated to Product discontinued due to AE, de/rechallenge updated accordingly for all events

Term highlighted by reporter updated to no, event stop date added, outcome updated to recovered for the event Saxenda was not prescribed by a physician

Treatment received updated to yes for Hypothyroidism

Narrative updated accordingly

company comment:

Hypothyroidism is assessed as an unlisted event, while nausea, me-tallic taste, vomiting, stomach pain, stomach discomfort, headache, and difficulty sleeping are assessed as listed events according to the current Novo Nordisk CCDS information on Saxenda.

Information on any autoimmune conditions, exposure to radiation, family history, or surgical history is not available, which limits a thorough medical evaluation. Considering the nature of the event and the pharmacologi-cal properties of the drug, causality for hypothyroidism is assessed as unlikely related to the drug.

This single case report is not considered to change the current knowledge of the safety profile of the product.

References included:

Reference Type: E2B Company Number

Reference ID#: CR-NOVOPROD-1472780

Reference Notes:

Reporter Comment: patient does not have any family history of headache, headache has not been triggered by specific factors like light, noise, food, etc.

Patient does not use Concomitant Medications.

Patient also mentions that no matter how much brushes the teeth, the iron taste doesn't dissappear.

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL; Regimen #2	3 mg, qd; Subcutaneous	overweight (Overweight)	Unknown / AUG-2025; Unknown

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
Unknown	Historical Condition	Obesity (Obesity);